给CKD患者服用益生菌会改变他们的微生物组和新陈代谢
Dominic S Raj1, Bei Gao2, Michael B Sohn3
1Division of Renal Diseases and Hypertension, George Washington University, Washington DC, USA.
概括
富含橄果糖的胰岛素 (p-胰岛素) 补充剂改善了慢性病 (CKD) 患者的肠道微生物功能和改变了代谢物. 这种预生菌干预转移了毒素生产向氨基酸合成,并有利地影响了脂质代谢.
科学领域:
- 微生物学 微生物学
- 代谢学 代谢学 代谢学
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 益生菌可以解决慢性病 (CKD) 中的肠道失调和代谢不良.
- 益生菌对CKD肠道元基因组和代谢组动态的具体影响尚不清楚.
研究的目的:
- 为了研究富含橄果糖的胰岛素 (p-胰岛素) 对肠道微生物元基因组和血,尿液和便代谢物的作用,在CKD患者中.
主要方法:
- 一个3阶段试验试验 (8周前期治疗,12周p-inulin治疗,8周后期治疗) 涉及13名CKD患者.
- 对便功能性元基因组和血,尿液和便代谢物的分析.
主要成果:
- 增加有益细菌 (Bifidobacterium, Lachnospiraceae) 的丰富性,并丰富碳水化合物降解和氨基酸生物合成途径.
- 减弱的尿素生物合成途径;激活的氨酸,氨酸和单氨酸的血代谢途径.
- 改变了脂质新陈代谢,减少了二次胆汁酸,尿液中减少了氧硫酸和p-cresol硫酸的水平.
结论:
- 服用P-胰岛素导致肠道微生物功能发生显著转变,从毒素生成转向氨基酸生物合成.
- 该干预导致脂质代谢的有利变化,并减少了CKD患者的关键尿素毒素.
相关概念视频
Chronic Kidney Disease III: Interprofessional Care
326
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
326
Chronic Kidney Disease I: Introduction
549
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
549
Chronic Kidney Disease II: Clinical Manifestations
531
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
531
Chronic Kidney Disease IV: Nursing Management
307
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
307
Acute Kidney Injury V: Interprofessional Care
284
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
284
Bioavailability: Influencing Factors
320
Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...
320


